SCHEDULE 13D/A

Kymera Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 501575104

Event date: 2025-12-11

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• BIOTECHNOLOGY VALUE FUND L PReported CIK 0000918923

  Shares: 3,550,766.00 · Class: 4.4%

• BVF I GP LLCReported CIK 0001803805

  Shares: 3,550,766.00 · Class: 4.4%

• BIOTECHNOLOGY VALUE FUND II LPReported CIK 0001102444

  Shares: 2,752,456.00 · Class: 3.4%

• BVF II GP LLCReported CIK 0001803806

  Shares: 2,752,456.00 · Class: 3.4%

• Biotechnology Value Trading Fund OS LPReported CIK 0001660683

  Shares: 406,145.00 · Class: 0.5%

• BVF Partners OS Ltd.Reported CIK 0001660684

  Shares: 406,145.00 · Class: 0.5%

• BVF GP HOLDINGS LLCReported CIK 0001803809

  Shares: 6,303,222.00 · Class: 7.8%

• BVF PARTNERS L P/ILReported CIK 0001055947

  Shares: 6,867,809.00 · Class: 8.5%

• BVF INC/ILReported CIK 0001056807

  Shares: 6,867,809.00 · Class: 8.5%

• LAMPERT MARK NReported CIK 0001233840

  Shares: 6,867,809.00 · Class: 8.5%

• Hrustanovic GorjanReported CIK 0001821194

  Shares: 100,190.00 · Class: 0.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.